Information Provided By:
Fly News Breaks for June 14, 2016
RVNC
Jun 14, 2016 | 07:28 EDT
SunTrust cut its price target on Revance after the company discontinued its RT001 topical development program for lateral canthal lines and excessive sweating due to negative Ph-3 REALISE-1 data. The firm notes that the company is still working on a number of additional treatments. It keeps a Buy rating on the shares.
News For RVNC From the Last 2 Days
There are no results for your query RVNC